FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979467592> ?p ?o ?g. }

• W2979467592 endingPage "5358" @default.
• W2979467592 startingPage "5349" @default.
• W2979467592 abstract "// Maud-Emmanuelle Gilles 1 , Liangliang Hao 2 , 3 , Kaelyn Brown 1 , Jihoon Lim 1 , Sangeeta N. Bhatia 2 , 3 , 4 , 5 , 6 , 7 and Frank J. Slack 1 1 HMS Initiative for RNA Medicine, Department of Pathology, Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA 2 Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA 3 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA 4 Department of Medicine, Brigham and Women&#x2019;s Hospital and Harvard Medical School, Boston, Massachusetts, USA 5 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA 6 Howard Hughes Medical Institute, Cambridge, Massachusetts, USA 7 Marble Center for Cancer Nanomedicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA Correspondence to: Frank J. Slack, email: fslack@bidmc.harvard.edu Keywords: miRNAs; KRAS; RNA-based-therapy; PDAC; tumor-penetrating nanocomplexes Received: March 28, 2019     Accepted: July 28, 2019     Published: September 03, 2019 ABSTRACT Developing new targeted therapy for pancreatic cancer is one of the major current challenges in cancer research. KRAS mutations and miRNA dysregulation (e.g. miR-21-5p oncomiR) play key roles in Pancreatic Ductal Adenocarcinoma (PDAC), leading to rapid progression of the disease. As the KRAS mutation is a main driver of PDAC, anti-KRAS strategies remain a major therapeutic approach for PDAC treatment. Previously, utilization of either siKRAS or small chemically modified single-stranded RNA molecules that specifically disable miR-21 (anti-miR-21) were effective in slowing PDAC tumor growth in various tumor models when packaged in an innovative delivery system (TPN) required for efficient drug delivery to the PDAC tumor site. Here we have tested the utility of targeting the KRAS pathway through multiple mechanisms and via dual targeting of a PDAC oncomiR and oncogene. Initially we found that miR-217, which has been shown to directly regulate KRAS expression, is downregulated in our PDAC samples, thus we tested the benefits of anti-miR-21, miR-217 mimic or siKRAS loaded into the tumor-penetrating nanoparticles (TPN) that we had previously shown to potently target the largely impenetrable PDAC tumors, and found an enhanced anti-tumoral response upon dual treatments in KRAS-mutated PDAC models." @default.
• W2979467592 created "2019-10-18" @default.
• W2979467592 creator A5013989133 @default.
• W2979467592 creator A5035270729 @default.
• W2979467592 creator A5039958236 @default.
• W2979467592 creator A5042296387 @default.
• W2979467592 creator A5083193445 @default.
• W2979467592 creator A5074127564 @default.
• W2979467592 date "2019-09-03" @default.
• W2979467592 modified "2023-10-10" @default.
• W2979467592 title "Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer" @default.
• W2979467592 cites W2019517037 @default.
• W2979467592 cites W2039225116 @default.
• W2979467592 cites W2043481243 @default.
• W2979467592 cites W2088832018 @default.
• W2979467592 cites W2107277218 @default.
• W2979467592 cites W2112417639 @default.
• W2979467592 cites W2114843025 @default.
• W2979467592 cites W2146177965 @default.
• W2979467592 cites W2149441684 @default.
• W2979467592 cites W2150006612 @default.
• W2979467592 cites W2158134441 @default.
• W2979467592 cites W2163326536 @default.
• W2979467592 cites W2165480504 @default.
• W2979467592 cites W2192080449 @default.
• W2979467592 cites W2514165095 @default.
• W2979467592 cites W2529869777 @default.
• W2979467592 cites W2539381937 @default.
• W2979467592 cites W2574695762 @default.
• W2979467592 cites W2608708957 @default.
• W2979467592 cites W2741508285 @default.
• W2979467592 cites W2757417448 @default.
• W2979467592 cites W2783164910 @default.
• W2979467592 cites W2783418022 @default.
• W2979467592 cites W2785043177 @default.
• W2979467592 cites W2886038660 @default.
• W2979467592 cites W4256412268 @default.
• W2979467592 doi "https://doi.org/10.18632/oncotarget.27160" @default.
• W2979467592 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6731108" @default.
• W2979467592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31523393" @default.
• W2979467592 hasPublicationYear "2019" @default.
• W2979467592 type Work @default.
• W2979467592 sameAs 2979467592 @default.
• W2979467592 citedByCount "15" @default.
• W2979467592 countsByYear W29794675922020 @default.
• W2979467592 countsByYear W29794675922021 @default.
• W2979467592 countsByYear W29794675922022 @default.
• W2979467592 countsByYear W29794675922023 @default.
• W2979467592 crossrefType "journal-article" @default.
• W2979467592 hasAuthorship W2979467592A5013989133 @default.
• W2979467592 hasAuthorship W2979467592A5035270729 @default.
• W2979467592 hasAuthorship W2979467592A5039958236 @default.
• W2979467592 hasAuthorship W2979467592A5042296387 @default.
• W2979467592 hasAuthorship W2979467592A5074127564 @default.
• W2979467592 hasAuthorship W2979467592A5083193445 @default.
• W2979467592 hasBestOaLocation W29794675921 @default.
• W2979467592 hasConcept C104317684 @default.
• W2979467592 hasConcept C121608353 @default.
• W2979467592 hasConcept C126322002 @default.
• W2979467592 hasConcept C143998085 @default.
• W2979467592 hasConcept C145059251 @default.
• W2979467592 hasConcept C2780210213 @default.
• W2979467592 hasConcept C2781187634 @default.
• W2979467592 hasConcept C2993838110 @default.
• W2979467592 hasConcept C39845236 @default.
• W2979467592 hasConcept C509550671 @default.
• W2979467592 hasConcept C526805850 @default.
• W2979467592 hasConcept C55493867 @default.
• W2979467592 hasConcept C555283112 @default.
• W2979467592 hasConcept C71924100 @default.
• W2979467592 hasConcept C86803240 @default.
• W2979467592 hasConceptScore W2979467592C104317684 @default.
• W2979467592 hasConceptScore W2979467592C121608353 @default.
• W2979467592 hasConceptScore W2979467592C126322002 @default.
• W2979467592 hasConceptScore W2979467592C143998085 @default.
• W2979467592 hasConceptScore W2979467592C145059251 @default.
• W2979467592 hasConceptScore W2979467592C2780210213 @default.
• W2979467592 hasConceptScore W2979467592C2781187634 @default.
• W2979467592 hasConceptScore W2979467592C2993838110 @default.
• W2979467592 hasConceptScore W2979467592C39845236 @default.
• W2979467592 hasConceptScore W2979467592C509550671 @default.
• W2979467592 hasConceptScore W2979467592C526805850 @default.
• W2979467592 hasConceptScore W2979467592C55493867 @default.
• W2979467592 hasConceptScore W2979467592C555283112 @default.
• W2979467592 hasConceptScore W2979467592C71924100 @default.
• W2979467592 hasConceptScore W2979467592C86803240 @default.
• W2979467592 hasIssue "51" @default.
• W2979467592 hasLocation W29794675921 @default.
• W2979467592 hasLocation W29794675922 @default.
• W2979467592 hasLocation W29794675923 @default.
• W2979467592 hasLocation W29794675924 @default.
• W2979467592 hasLocation W29794675925 @default.
• W2979467592 hasOpenAccess W2979467592 @default.
• W2979467592 hasPrimaryLocation W29794675921 @default.
• W2979467592 hasRelatedWork W1595251103 @default.
• W2979467592 hasRelatedWork W1606537025 @default.
• W2979467592 hasRelatedWork W1712525759 @default.
• W2979467592 hasRelatedWork W22582601 @default.

• next